August 2026 Research Update

This month, studies focused on a practical problem: low alkaline phosphatase (ALP) can be a strong clue for hypophosphatasia (HPP), but it does not neatly separate who does and does not have HPP. In adults being evaluated for bone health, combining ALP with additional blood markers and ALPL genetic testing appeared to improve certainty, and fracture history did not line up perfectly with whether an ALPL variant was found. [1]

In a small adult cohort referred for suspected osteoporosis, an ALP of 25 IU/L or less identified people who had a disease-causing ALPL variant, but some people with higher (still low) ALP could still have HPP. A vitamin B6-related blood marker (PLP) differed between those with and without ALPL variants, while common bone density results looked similar, suggesting that bone density scans alone may miss HPP-related bone problems. [1]

A much larger screening effort in Russia used targeted genetic panel testing in nearly 5000 people referred for suspected HPP and found a disease-causing variant in the HPP gene (ALPL) in about 7% overall, rising to about 12% at the larger center once referral criteria were tightened. The same screening also identified variants in other bone-related genes, which matters because some people referred as possible HPP may actually have different inherited bone conditions that can look similar at first. [2]

For patients, this adds clarity about why HPP can be hard to confirm in adults who are first labeled with osteoporosis or unexplained fractures. These results support the idea that very low ALP can be a strong sign, but that ALP level alone does not tell the whole story, and that adding targeted blood markers (like PLP) and genetic testing can help explain symptoms and fracture history. This is evidence from real patient cohorts, but the adult ALP-and-fracture findings came from only 33 people, and the large genetic screening reflects a referred (higher-suspicion) population, so the exact detection rates may not match every clinic. [1] [2]

These studies add a clearer picture that adult HPP is often experienced as ongoing musculoskeletal symptoms, and that blood markers linked to bone and mineral balance may also reflect other parts of health. The clinical registry emphasized what people report and live with, while the biomarker study explored how HPP-related changes show up in the bloodstream. [3] [4]

In a registry from five Central and Eastern European countries, chronic musculoskeletal pain was the most common reported problem, and low ALP was present in nearly all people with available detailed data. Fractures were also frequent, while classic osteoporosis on bone density testing appeared uncommon in the subset with scans, reinforcing that HPP bone fragility is not always captured by standard osteoporosis labels. [3]

In a small comparison study of adults with genetically confirmed HPP versus matched controls, osteoglycin (a protein linked to bone matrix) was lower and sclerostin (a protein that can slow bone formation signals) was higher in HPP. Osteoglycin tracked most closely with markers related to mineralization, while sclerostin tracked with a wider set of measures including blood sugar control, inflammation markers, kidney function, and cardiovascular risk estimates, suggesting possible connections that need follow-up over time. [4]

For patients and caregivers, this month strengthens a simple point: adult HPP commonly involves long-lasting pain and fractures even when a bone density scan does not look like typical osteoporosis. The biomarker results are early research and do not yet change routine care, but they help explain why some people with HPP may have health patterns that extend beyond the skeleton, which could matter later if confirmed in larger and longer studies. What remains uncertain is whether these blood marker differences predict symptoms, future fractures, or other complications over time. [3] [4]

This month included several individual patient reports that expand what clinicians and researchers are watching for in HPP, but they do not prove what will happen for others. Taken together, they show both potential symptom improvement during enzyme-related treatment and rare or unexpected complications or presentations that merit further study. [5] [6] [7]

One adult case with a single heterozygous ALPL variant reported substantial improvement in pain, upper-limb range of motion, and walking after subcutaneous aspartate phosphatase alpha therapy. Because this was a single person without a comparison group, it is best read as an early signal that some adults with HPP-like symptoms may experience noticeable day-to-day changes during this type of therapy. [5]

Two pediatric cases treated with asfotase alfa (enzyme replacement therapy) developed pan-craniosynostosis (early fusion of multiple skull sutures) and required cranial surgery, with generally favorable postoperative recovery described. The authors raised the possibility that the skull changes could be related to treatment-driven shifts in bone mineralization, but cause-and-effect could not be confirmed from 2 cases. [6]

A separate case described a woman with progressive parkinsonism features who had a low-normal ALP and an ALPL frameshift variant found on whole-exome sequencing, with minimal improvement on modest dopaminergic therapy. The report suggested a possible mild adult HPP phenotype and a potential connection to parkinsonism, but it also noted missing typical skeletal features and limited HPP substrate testing, so the relationship remains uncertain. [7]

For patients, these reports mainly matter as awareness-building rather than as proof of benefit or risk for most people. The adult treatment case highlights that some individuals report meaningful improvements in pain and mobility during enzyme-type therapy, while the pediatric cases highlight that skull growth and suture changes may need careful attention during asfotase alfa treatment, even though it is unclear how often this occurs or why. The parkinsonism case broadens the conversation about how ALPL variants might show up outside classic bone and tooth symptoms, but it is too early to know whether this is a real pattern or a coincidence. [5] [6] [7]